The evaluation of chronic obstructive pulmonary disease (COPD) patients with COVID-19 did not find increased mortality, nor a negative impact of exacerbation status. Similar results were found for asthma and COVID-19. “We sought to assess whether COPD or asthma are risk factors for intubation in COVID-19, as well as mortality in COVID-19,” Dr Jacob Schwartz (Lenox Hill Hospital, NY, USA)…
Category: COPD
Introduction Over the past two centuries, there has been a gradual paradigm change in the way we look at chronic inflammatory airway diseases, including asthma and chronic obstructive pulmonary disease (COPD), shifting away from prototypic, organ-centred disease labels, coined by William Osler at the end of the 19th century, to differentiated disease subsets [1]. During the second half of the…
New research shows that the asthma drug benralizumab did not statistically decrease annual COPD exacerbation rates for patients with moderate to very severe COPD, a history of frequent moderate and/or severe exacerbations, and eosinophilic inflammation; although the team did report numeric decreases (GALATHEA/TERRANOVA trials). The data were published in the New England Journal of Medicine in conjunction with Prof. Gerard…